NCCN Guideline Updates in Clear-Cell RCC
Medical experts will discuss the updated NCCN guidelines favoring ipilimumab + plus nivolumab for patients with favorable risk, including the data supporting this change and its the potential impact on the disease landscape.
EP: 1.Overview of RCC: Clear-Cell and Non–clear Cell
EP: 2.Challenges in Treating RCC From Community and Academic Settings
EP: 3.Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
EP: 4.KEYNOTE-B61: Clinical Implications of Efficacy and Safety Data in Practice
EP: 5.nccRCC: Alternative Therapies
EP: 6.Role of Histology and Data in Selecting Optimal Therapy in nccRCC
EP: 7.AE Management of IO/TKI and Future of nccRCC
EP: 8.KEYNOTE-564: Pembrolizumab as Adjuvant Therapy
EP: 9.NCCN Guideline Updates in Clear-Cell RCC
EP: 10.Best Treatment Selection in Clear-Cell RCC
Video content above is prompted by the following:
NCCN guidelines have been updated to reflect ipilimumab + plus nivolumab as a preferred regimen in patients with favorable risk. What data supported this change, and how do you see it affecting the disease landscape?
Prolaris in Practice: Guiding ADT Benefits, Clinical Application, and Expert Insights From ACRO 2025
April 15th 2025Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.
Recap: Recent Advances in the Treatment of Metastatic Castration-Sensitive Prostate Cancer
September 18th 2022Expert oncologists review key studies in the metastatic castration-resistant prostate cancer treatment landscape and discuss how evidence can be applied to clinical practice to improve patient outcomes.
CCR Scores and Beyond: Precision Strategies for Treatment Intensification in Prostate Cancer
April 15th 2025Alvaro Martinez, MD discusses how emerging genomic risk stratification tools such as the clinical cell-cycle risk (CCR) score are transforming personalized prostate cancer treatment by enabling more nuanced assessments of metastasis risk and treatment intensification strategies beyond traditional NCCN risk groupings.
Recap: Updates in Treatment of HER2-Positive Breast Cancer and Brain Metastases
July 16th 2022Sara A. Hurvitz, MD; Stefania Maraka, MD; and Ruta Rao, MD, discuss the evolving landscape of metastatic HER2+ breast cancer, highlighting recent clinical trials and the management of patients with brain metastases.
Recap: Emory Experts Review Treatment Strategies for Transplant-Ineligible Multiple Myeloma
June 20th 2022A panel of experts from Emory University review several key data updates in multiple myeloma from recent meetings and discuss how the data can be applied to clinical practice to improve patient outcomes.
